Adlai Nortye Limited - ADR
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Adlai Nortye Limited - ADR
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
/ 
Frequently asked questions
To buy Adlai Nortye Limited - ADR stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Adlai Nortye Limited - ADR by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Adlai Nortye Limited - ADR is ANL:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Adlai Nortye Limited - ADR has its primary listing on NASDAQ. You can trade Adlai Nortye Limited - ADR with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Adlai Nortye Limited - ADR is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Adlai Nortye Limited - ADR as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Adlai Nortye Limited - ADR.